Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862163 | 0.84 | GSK3B (0.35) | KMT2A | |
| SCHEMBL841452 | 0.83 | ACKR3 (0.40) | ACKR3SMN1; SMN2FGFR1 | |
| SCHEMBL862382 | 0.82 | KDM4E (0.38) | MEN1KMT2A | |
| SCHEMBL22167019 | 0.76 | ACKR3 (0.40) | ACKR3CCNKCDK12IDO1TDO2 | |
| SCHEMBL862385 | 0.75 | POLB (0.37) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17481790 | 0.70 | ACKR3 (0.42) | ACKR3CCNKCDK12IDO1TDO2 | |
| SCHEMBL22166943 | 0.70 | VEGFA (0.44) | ACKR3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26885980 | 0.69 | ALDH1A1 (0.39) | ACKR3KMT2ASMN1; SMN2IDO1TDO2 | |
| SCHEMBL13535201 | 0.69 | VEGFA (0.47) | MEN1CYP2C19KMT2ASMN1; SMN2IDO1 | |
| SCHEMBL22166944 | 0.68 | ACHE (0.48) | ACKR3TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143057-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2012-03-27 | — | — | US | disclosed |
| US-8071626-B2 | Chromophoric moiety comprises trialkoxyphenylpyridyl groups; biochemical conjugation; for solid phase synthesis of oligonucleotides and oligopeptides; magnetic resonance imaging; positron emission tomography | WALLAC OY (FI) | 2011-12-06 | — | — | US | disclosed |
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | WALLAC OY (FI) | 2010-02-11 | — | — | US | disclosed |
| US-7625930-B2 | Chelating agents and highly luminescent and stable chelates and their use | WALLOC OY (FI) | 2009-12-01 | — | — | US | disclosed |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | WALLAC OY (FI) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036102-A1 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE | CLTA, CLTC, FOLH1 | ACKR3 560/4885CCNK 2360/4885CDK12 1449/4885 |
| US-20080167443-A1 | Novel chelating agents and highly luminescent and stable chelates and their use | CLTA, CLTC, FOLH1 | ACKR3 560/4885CCNK 2360/4885CDK12 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.